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Factors related to the incidence of CTCAE 3.0 Grade 2 or worse 
pulmonary fibrosis induced by neoadjuvant platinum-based 
chemotherapy and thoracic radiotherapy: A prospective study
Xie, Liyi; Fan, Ming; Cai, Xuwei; Jiang, Guoliang 
Department of Radiation Oncology,Cancer Hospital,Fudan University, 
Shanghai, China
Purpose: To investigate,prospectively,clinical,physical parameters 
and changes in serum interleukin-1α(IL-1α), IL-1β, IL-6,IL-7, tumor 
necrosis factor-α (TNF-α), transforming growth factor-β1(TGF-β1) 
and manganese superoxide dismutase (MnSOD) as indicators for CT-
CAE3.0 ≥Grade2 pulmonary ﬁbrosis induced by neoadjuvant platinum-
based chemotherapy and thoracic radiotherapy(TRT).
Methods: Between January and December 2004, 86 patients (66 with 
lung cancer,10 esophageal cancer, 5 malignant thymoma, 5 mediasti-
num tumor) who received incidental thoracic irradiation and neoadju-
vant platinum-based chemotherapy were enrolled in this prospective 
study. There were 9 females and 77 males(median age, 57 years; range, 
19-74). The median follow-up was 96 days (range, 30-557). All patients 
received neoadjuvant platinum-based chemotherapy. Chemo-regimen 
included NP, NIP, EP, IEP and CAP. The medium pre-RT cycle was 
one (range, 1-6). Radiation dose ranged 30-66Gy.Cad-plan™v6.08 and 
Pinnacle3™v7.0 treatment planning system were applied to generate 





10Gy increments. Serial serum concentration of IL-1α, IL-1β, IL-6, 
IL-7, TNF-α, TGF-β1 and MnSOD were determined by enzyme-
linked immunosorbent assay (ELISA) prior to and weekly during RT. 
Since great inter-patient divergence was revealed for baseline serum 
cytokines and MnSOD levels,we calculated week1/pre-RT ratios (w1/0 
ratio, deﬁned as serum concentration in the 1st week of RT/Pre-RT 
level) as surrogates.On univariate analysis,various dosimetric,serum 
cytokines,serum MnSOD,smoking history(<20 pack-year vs.≥20 
pack-year) and clinical parameters (conventional RT vs.non-conven-
tional RT, age) were studied. Hazard ratios(HRs) were estimated by 
Cox proportional hazard models for indicators to CTCAE3.0 Grade≥2 
pulmonary ﬁbrosis.
Results: Six of 86(7%) patients developed CTCAE3.0 Grade≥2 pulmo-
nary ﬁbrosis. Two developed Grade2 ﬁbrosis (proportion of total lung 
volume that is ﬁbrotic is 25-<50%), 2 Grade3 (50-<75%), 2 Grade4 
(≥75% or honeycombing) and 0 Grade5 (death). On univariate analysis, 
no single parameter signiﬁcantly correlated with severe pulmonary 
ﬁbrosis.IL-7 w1/0 ratio approached marginal statistical signiﬁcance 
(p=0.06). On multivariate analysis,baseline FEV1(p=0.0352, HR 
0.062) was signiﬁcantly associated with ≥Grade2 pulmonary ﬁbrosis.
A trend towards signiﬁcant correlation with ﬁbrosis was observed for 
IL-1β w1/0 ratio and TGF-β1 w1/0 ratio,p=0.0716(HR 7.929) and 
p=0.0925(HR 2.561),respectively. 
Conclusions: Baseline FEV1 seemed to signiﬁcantly associate with 
CTCAE3.0 Grade≥2 pulmonary ﬁbrosis in this group of patients.IL-1β 
w1/0 ratio and TGF-β1 w1/0 ratio were meanwhile marginally signiﬁ-
cant indicators. However,since only a few events were observed,care 
should be taken in interpreting the present ﬁndings.
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Results of hypofractionated radiotherapy (2 x 8 Gy) for patients 
with brain metastases from lung cancer
Bolukbasi, Yasemin; Yalman, Deniz; Akcay, Cimen; Ozkok, Serdar 
Ege University, Izmir, Turkey
Purpose: Brain metastases will develop in 25% of patients with lung 
cancer at some point in the course of their disease and radiotherapy is 
the mainstay of treatment for the palliation of brain metastases. The 
aim of this study is to evaluate the clinical and radiologic response 
rates, toxicity and tolerability of 2 x 8 Gy whole brain radiotherapy 
(WBRT) in lung cancer patients with brain metastases and to identify 
the prognostic factors for survival.
Materials and Methods: 2 x 8 Gy WBRT was performed in 126 lung 
cancer patients with brain metastases during 2002 and 2006 at the 
Radiation Oncology Department of Ege University Hospital.
Results: Twenty-three patients had small cell and 103 had nonsmall 
cell lung cancer. Pretreatment median Karnofsky performance score 
was 70 (range 20-90). In 62 patients (49.2%) the brain metastases were 
synchronous with the primary tumor. In metachronous metastases 
median time to metastases was 6 months (range 1-25 months). Median 
number of metastatic foci was 3 (range 1-8). Treatment was tolerated 
well. Clinical response rates were as follows: complete response 31%; 
good partial response 30.2%; partial response 21.4%; stable disease 
7.9% and progressive disease 5.6%. Radiological response was evalu-
ated in 54 patients and the response rates were as follows: complete 
response 7.4%; good partial response 5.6%; partial response 35.2%, 
stable disease 44.4% and progressive disease 7.4%. Median palliation 
and survival duration was 57 and 80 days respectively. Two and 6-
month survival rates were 59.5% and 25.4% respectively. Performance 
status, age, hemoglobin level, metachronous metastases, localization, 
status of the primary tumor, response to steroid treatment, response 
rate, presence of other metastases, chemotherapy, serum lactate de-
hydrogenase level were identiﬁed as prognostic factors for survival. 
According to “Recursive Partioning Analysis” 6 month-survival rates 
for Groups 1, 2 and 3 were 61.5%, 41.6% and 33.9% respectively 
(p=0.002). Reirradiation was performed in 11 patients within a median 
of 5 months (range 4-12 months). 
Conclusion: Hypofractionated radiotherapy of 2 x 8 Gy provides simi-
lar palliation and survival rates when compared with other fractionation 
schedules and it is tolerable. The prognostic factors such as perfor-
mance status, age, status of the primary tumor, response to steroid treat-
ment, presence of other metastases, and serum lactate dehydrogenase 
level are also consistent with the literature. However the late morbidity 
of this schedule is unknown at the moment so its use could be restricted 
to patients with poor performance status with a short life expectancy.
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